Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-Kidney Augment in T2DM and CKD
NCT02008851Phase 1Terminated
- Sponsor
- Tengion, Inc.
- Start
- Dec 2013
- Primary completion
- Dec 2014
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rilparencel in chronic kidney disease (CKD), sponsored by Tengion, Inc. Primary endpoint: Number of adverse events related to study procedures or investigational product at 12 months. Started Dec 2013; status: terminated.
02
Drugs
rilparencel
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02008851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02008851.